Here's a new summary of all the drugs in the pipeline currently being evaluated for the treatments of vasculitis.

The immunoglobulin A IgA vasculitis market size has shown solid growth in recent years, escalating from $1.53 billion in 2024 to $1.63 billion in 2025, indicating a compound annual growth rate CAGR of ...

Vasculitis, a severe blood vessel condition, drives the global market's growth due to advancements in biologic treatments like monoclonal antibodies. Enhanced diagnostics and personalized medicine ...

Adenosine deaminase 2 (ADA2) plays a critical role in immune regulation, particularly in monocyte differentiation and ...

RA primarily affects the joints, but it can also cause symptoms in other areas of the body, such as the skin. Learn how RA ...

Dr. Kimberly Trotter distilled four high-impact disease clusters—gout, rheumatoid arthritis (RA), systemic lupus ...

The reemergence of myeloperoxidase-antineutrophil cytoplasmic antibodies — or MPO-ANCA — can serve as a biomarker to predict relapse in patients who achieved remission in MPO-ANCA–positive ...

A woman in her 40s with a history of a subarachnoid haemorrhage complicated by ischaemic infarcts presented with 1 week of ...

EYP-1901 shows promising results in reducing treatment burden for diabetic macular edema, offering sustained improvements in ...

Distinct patterns on chest computed tomography (CT) scans among patients with interstitial lung disease (ILD) and antineutrophil cytoplasmic antibody-associated vasculitis (AAV) are linked to varied ...

Patients with systemic lupus erythematosus who received autologous chimeric antigen receptor T-cell therapy enjoyed potent ...